MX2022003077A - Terapias de combinacion de antibioticos. - Google Patents
Terapias de combinacion de antibioticos.Info
- Publication number
- MX2022003077A MX2022003077A MX2022003077A MX2022003077A MX2022003077A MX 2022003077 A MX2022003077 A MX 2022003077A MX 2022003077 A MX2022003077 A MX 2022003077A MX 2022003077 A MX2022003077 A MX 2022003077A MX 2022003077 A MX2022003077 A MX 2022003077A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapies
- antibiotic combination
- antibiotic
- cefiderocol
- baumannii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899257P | 2019-09-12 | 2019-09-12 | |
| US201962902019P | 2019-09-18 | 2019-09-18 | |
| US201962941160P | 2019-11-27 | 2019-11-27 | |
| US202062977659P | 2020-02-17 | 2020-02-17 | |
| PCT/IB2020/000645 WO2021048610A1 (en) | 2019-09-12 | 2020-08-03 | Antibiotic combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003077A true MX2022003077A (es) | 2022-07-11 |
Family
ID=72432957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003077A MX2022003077A (es) | 2019-09-12 | 2020-08-03 | Terapias de combinacion de antibioticos. |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US11207305B2 (https=) |
| EP (3) | EP4028001B1 (https=) |
| JP (4) | JP7769605B2 (https=) |
| KR (1) | KR20220103698A (https=) |
| CN (3) | CN115052597B (https=) |
| AU (2) | AU2020344214B2 (https=) |
| BR (2) | BR112022004672A2 (https=) |
| CA (2) | CA3154317A1 (https=) |
| ES (1) | ES2982067T3 (https=) |
| HR (1) | HRP20240818T1 (https=) |
| HU (1) | HUE066936T2 (https=) |
| MX (1) | MX2022003077A (https=) |
| PH (1) | PH12022550610A1 (https=) |
| PL (1) | PL4028001T3 (https=) |
| RS (1) | RS65681B1 (https=) |
| SM (1) | SMT202400250T1 (https=) |
| WO (2) | WO2021048610A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230364065A1 (en) * | 2022-05-16 | 2023-11-16 | BioVersys AG | Antibiotic combination therapies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645508B1 (en) * | 1999-06-18 | 2003-11-11 | Jivn-Ren Chen | Stable L-ascorbic acid composition |
| CN101362067A (zh) * | 2007-08-06 | 2009-02-11 | 天津科技大学 | 一种微胶囊制备方法 |
| PT2247291T (pt) * | 2008-02-08 | 2019-02-01 | Red Hill Biopharma Ltd | Métodos e composições para tratamento de doença inflamatória do intestino |
| MY158809A (en) | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| EA016410B1 (ru) | 2010-11-13 | 2012-04-30 | Ооо "Нпк Наносистема" | Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты) |
| US10064858B2 (en) * | 2011-01-31 | 2018-09-04 | The United States Of America, As Represented By The Secretary Of The Army | Methods and compositions for treating bacterial infections with iron chelators |
| CN102178604B (zh) | 2011-03-22 | 2014-03-05 | 中国人民解放军第三0九医院 | 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球 |
| RU2472512C1 (ru) * | 2011-12-06 | 2013-01-20 | Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" | Противотуберкулезная композиция и способ ее получения |
| WO2016013986A1 (en) * | 2014-07-25 | 2016-01-28 | Agency For Science, Technology And Research | Antibiotic compositions for treating bacterial infections |
| CN107148479A (zh) * | 2014-09-04 | 2017-09-08 | 赛拉诺斯股份有限公司 | 病原体和抗微生物剂抗性检测 |
| US9763996B2 (en) | 2015-01-16 | 2017-09-19 | Northern Antibiotics, Ltd. | Polymyxin derivative and uses thereof |
| EP3291798A4 (en) * | 2015-05-04 | 2019-01-16 | Gufic Biosciences Limited | FREEZE-DRIED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND METHOD FOR THE PRODUCTION THEREOF |
| JP7072898B2 (ja) * | 2016-08-16 | 2022-05-23 | ユニバーシティ オブ ロチェスター | ポリミキシンｂ／トリメトプリム系の治療薬を含有する医薬組成物 |
| JP2020506236A (ja) | 2017-02-07 | 2020-02-27 | エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ | 長期間持続するオートファジー誘発のための同位体増強アンブロキソール |
| US11701346B2 (en) * | 2018-11-28 | 2023-07-18 | University Of Southern California | Rifabutin for the treatment of acinetobacter baumannii |
-
2020
- 2020-08-03 PH PH1/2022/550610A patent/PH12022550610A1/en unknown
- 2020-08-03 CN CN202080077930.0A patent/CN115052597B/zh active Active
- 2020-08-03 JP JP2022516161A patent/JP7769605B2/ja active Active
- 2020-08-03 US US16/983,718 patent/US11207305B2/en active Active
- 2020-08-03 KR KR1020227012086A patent/KR20220103698A/ko active Pending
- 2020-08-03 AU AU2020344214A patent/AU2020344214B2/en active Active
- 2020-08-03 JP JP2022516163A patent/JP7804570B2/ja active Active
- 2020-08-03 HR HRP20240818TT patent/HRP20240818T1/hr unknown
- 2020-08-03 EP EP20768692.4A patent/EP4028001B1/en active Active
- 2020-08-03 AU AU2020347536A patent/AU2020347536B2/en active Active
- 2020-08-03 US US16/983,689 patent/US11351158B2/en active Active
- 2020-08-03 CA CA3154317A patent/CA3154317A1/en active Pending
- 2020-08-03 BR BR112022004672A patent/BR112022004672A2/pt unknown
- 2020-08-03 PL PL20768692.4T patent/PL4028001T3/pl unknown
- 2020-08-03 HU HUE20768692A patent/HUE066936T2/hu unknown
- 2020-08-03 CN CN202511016208.7A patent/CN120860031A/zh active Pending
- 2020-08-03 ES ES20768692T patent/ES2982067T3/es active Active
- 2020-08-03 RS RS20240688A patent/RS65681B1/sr unknown
- 2020-08-03 MX MX2022003077A patent/MX2022003077A/es unknown
- 2020-08-03 CA CA3154129A patent/CA3154129A1/en active Pending
- 2020-08-03 EP EP24169078.3A patent/EP4420673A3/en active Pending
- 2020-08-03 WO PCT/IB2020/000645 patent/WO2021048610A1/en not_active Ceased
- 2020-08-03 EP EP20768691.6A patent/EP4028000A1/en active Pending
- 2020-08-03 CN CN202080077348.4A patent/CN114980889A/zh active Pending
- 2020-08-03 BR BR112022004645A patent/BR112022004645A2/pt unknown
- 2020-08-03 SM SM20240250T patent/SMT202400250T1/it unknown
- 2020-08-03 WO PCT/IB2020/000647 patent/WO2021048611A1/en not_active Ceased
-
2021
- 2021-12-27 US US17/562,496 patent/US11766425B2/en active Active
-
2022
- 2022-06-06 US US17/833,326 patent/US11833139B2/en active Active
-
2023
- 2023-10-20 US US18/491,243 patent/US12257241B2/en active Active
-
2025
- 2025-03-24 US US19/088,662 patent/US20250281469A1/en active Pending
- 2025-09-02 JP JP2025145104A patent/JP2025176113A/ja active Pending
- 2025-10-31 JP JP2025184422A patent/JP2026016690A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000596S1 (es) | Auriculares. | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| CL2020000594S1 (es) | Estuche de auriculares. | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| MX379270B (es) | Composiciones que comprenden cepas bacterianas. | |
| CL2020000174S1 (es) | Automóvil. | |
| MX394160B (es) | Composiciones que comprenden cepas bacterianas. | |
| MD3360559T2 (ro) | Compoziții conținând tulpini bacteriene | |
| CR20220156A (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso | |
| JOP20210050B1 (ar) | معدلات تعبير pnpla3 | |
| GEP20227406B (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| EP4616910A3 (en) | Pcna inhibitors | |
| EA201991818A1 (ru) | Лечение рака | |
| EP4700161A3 (en) | Direct-to-library methods, systems, and compositions | |
| ZA202102702B (en) | Synergistic disinfectant compositions having enhanced antimicrobial efficacy and stability, and methods of using the same | |
| EP4378535A3 (en) | Antibiotic formulations for lower back pain | |
| JOP20190190B1 (ar) | معالجة سرطان | |
| MX2020004072A (es) | Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm). | |
| MX2022007626A (es) | Combinaciones. | |
| CL2020000224S1 (es) | Automóvil. | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| JOP20210216A1 (ar) | علاج السرطان | |
| BR112018072664A2 (pt) | composições e métodos para tratamento de inflamação e infecção do olho | |
| MX2022003077A (es) | Terapias de combinacion de antibioticos. |